Cardiovascular Safety of Celecoxib: 2016 PRECISION Trial Overview

Study Background

In 2016, a significant trial examined the cardiovascular safety of the COX-2 inhibitor celecoxib in comparison to the nonspecific COX inhibitors ibuprofen and naproxen. Findings from the study indicated that, at moderate doses, celecoxib poses no greater cardiovascular risk than its counterparts.

Concerns Over Higher Doses

Previous reports have raised concerns regarding the potential cardiovascular risks associated with higher doses of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) commonly used for arthritis pain. This prompted the U.S. Food and Drug Administration (FDA) to require a trial focused on the cardiovascular safety of celecoxib.

Details of the PRECISION Trial

Trial Design and Participants

The 2016 PRECISION trial, published in the New England Journal of Medicine, aimed to evaluate the safety of celecoxib against ibuprofen and naproxen. The study recruited adult patients with osteoarthritis or rheumatoid arthritis who were at increased risk for cardiovascular events and were already on a daily NSAID prescription. Participants could continue low-dose aspirin (under 325 mg daily) unless their pain was sufficiently managed with acetaminophen, in which case they were excluded from the study.

Dosing and Treatment Protocol

Participants were assigned to receive either 100 mg of celecoxib twice daily, 600 mg of ibuprofen three times daily, or 375 mg of naproxen twice daily. For those with insufficient pain relief, dosages could be escalated to 200 mg of celecoxib, 800 mg of ibuprofen, or 500 mg of naproxen. Additionally, all patients were prescribed 20-40 mg of daily esomeprazole to minimize gastric upset.

Safety Outcomes Measured

The safety assessment focused on the time until non-fatal heart attacks, strokes, or cardiovascular deaths, along with other serious health events like gastric complications, kidney dysfunction, and hospitalization due to cardiovascular issues. Pain levels were evaluated using a visual analog scale (VAS), where higher scores indicated greater pain, with significant differences noted at scores of 13.7 mm or more.

Trial Results

Participant Overview

Among the 24,222 patients enrolled, 24,081 completed the trial. The distribution included 8,072 in the celecoxib group, 8,040 in the ibuprofen group, and 7,969 in the naproxen group. The average treatment duration was 20.3 months, with follow-up lasting 34.1 months.

Cardiovascular Events and Risks

Nonfatal heart attacks, strokes, or cardiovascular deaths were recorded in 188 patients (2.3%) in the celecoxib group, 218 (2.7%) in the ibuprofen group, and 201 (2.5%) in the naproxen group. Celecoxib users were found to be 15% less likely to experience these outcomes compared to ibuprofen users and 7% less likely than those on naproxen. For those who completed the trial, rates were 1.7% for celecoxib, 1.9% for ibuprofen, and 1.8% for naproxen, indicating a 19% lower risk for celecoxib users compared to ibuprofen and a 10% lower risk compared to naproxen.

Gastrointestinal and Kidney Event Rates

Among those who completed the trial, nonfatal heart attacks were 39% more common in the ibuprofen group compared to the naproxen group. Serious gastrointestinal events were 29% less frequent in the celecoxib group compared to naproxen and 35% less compared to ibuprofen, while rates were 8% higher in the ibuprofen group versus naproxen. Serious kidney events were 39% lower in the celecoxib group compared to ibuprofen, and hospitalizations due to high blood pressure were 40% lower for celecoxib users than ibuprofen users.

Pain Management Outcomes

Pain reduction, as measured by VAS scores, averaged a decrease of 9.3 mm for celecoxib, 9.5 mm for ibuprofen, and 10.2 mm for naproxen, although these changes were not statistically significant.

Conclusions and Future Research Directions

The findings indicate that celecoxib is comparably safe to ibuprofen and naproxen regarding cardiovascular risk. Additionally, the rate of kidney and gastrointestinal events, as well as hospitalizations due to high blood pressure, were lower or similar to those seen with the non-specific NSAIDs. However, the impact of esomeprazole adherence on gastrointestinal events was not evaluated, and the effect of aspirin on cardiovascular outcomes remains unclear. Given that approximately 90% of the study population had osteoarthritis, future research should explore the safety of celecoxib in relation to other NSAIDs across different patient groups.

Written By: Raishard Haynes, MBS